Antidiabetic agents Flashcards
diazoxide functions (3)
directly inhibit insulin secretion
decreased peripheral glucose utilization
increased hepatic glucose production
diazoxide drug type (3 things)
non-diuretic thiazide
vasodilator
hyperglycemic
sulfonylureas MOA (2)
stimulate insulin release from pancreatic B-cells
indirectly potentiate action of insulin on target tissues
Tolbutamine, Chlorpropamide, Tolzamide drug class
Sulfonylureas 1st gen
sulfonylureas adverse effects (3)
renal disease
hepatic dysfunction
weight gain
sulfonylureas contraindications
renal disease
hepatic dysfunction
sulfa
tolbutamide (2 special characteristics)
rapid
safest in the elderly
chlorpropamide (2 special things)
disulfram-like effect
worst hypoglycemia
1st gen sulfonylureas (3)
Tolbutamide
Chlorpropamide
Tolzamide
Glyburide, Gliphizide, Glimepiride
drug class
2nd gen sulfonylureas
2nd gen sulfonylureas (3)
Glyburide
Glipizide
Glimepiride
Glyburide
worst hypoglycemia
Glipizide (special characteristic)
least hypoglycemia of 2nd gens
Glimepiride (2)
daily dosing
smaller hypoglycemic effect
meglitinides (2)
Repaglinide (Prandin)
Nateglinide (Starlix)
Repaglinide & Nateglinide drug class
Meglitinides
meglitinides MOA
binds to receptors on K+ channels on B-cells —> increased insulin release
meglitinides effects (3)
decreased postprandial glucose
rapid/short action
decreased HbA1c
meglitinides administration (3)
oral
preprandial administration
peak effect at 1 hour
meglitinides cautions/contraindications (3)
not used w/ sulfonylureas
caution w/ liver impairment
hypoglycemia
Metformin (Glucophage) actions (4)
increased glucose uptake (increased insulin action)
decreased glucose absorption from the GI
decreased glucagon
decreased gluconeogenesis
Metformin bonus effects (3)
dereased plasma TGs
no weight gain
decreased macrovascular events
Metformin adverse effects (3)
lactic acidosis
crazy diarrhea
n/v
metformin contraindications
Lactic Acidosis conditions: renal/hepatic disease, alcoholism tissue hypoxia (CHF, COPD)
thiazolidinediones/TZDs (2)
Pioglitazone (Actos)
Rosiglitazone (Avandia)
Pioglitazone (Actos) & Rosiglitazone (Avandia)
drug class
TZDs
TZD MOA (3)
insulin sensitizers
insulin-mimetic action via ligands of the nuclear PPAR receptor
increase glucose transporter synthesis in adipose
TZD effects (3)
decreased insulin resistance
long term TG decrease
slight increase in HDL
TZD special use
prophylactic for type 2 diabetes
TZD that is contraindicated in hx MI or angina
Rosiglitazone (Avandia)
TZD adverse effects (5)
edema weight gain back pain fatigue headache
a-glucosidase inhibitors (2)
Acarbose (Precose)
Miglitol (Glyset)
Acarbose (Precose) & Miglitol (Glyset)
drug class
a-glucosidase inhibitors
a-glucosidase inhibitor MOA & effect
inhibit a-glucosidases in small intestine —> delayed carbohydrate digestion & absorption —> reduced glucose absorption
a-glucosidase results (4)
decreased postprandial glucose
minimal effects of fasting glucose
decreased HA1c
no weight effects
adverse effects of a-glucosidase inhibitors (3)
GI- farting!!
increased hepatic enzymes
jaundice
a-glucosidase inhibitor contraindications (3)
GI disease
hepatic disease
renal impairment
incretin mimetic MOA and effects (3)
resistant to degradation by DPP-IV
increased insulin
decreased glucagon release
decreased hepatic gluconeogenesis
incretin mimetics (3)
Exenatide (Byetta)
Liraglutide (Victoza)
Dulaglutide (Trulicity)
Exenatide (Byetta), Liraglutide (Victoza), Dulaglutide (Trulicity)
drug class & MOA
incretin mimetics
resistant to degradation by DPP-IV
incretin mimetics effects on diabetes (3)
decreased postprandial & fasting glucose
increased B-cell number & function
slows gastric emptying —> weight loss
Exenatide administration?
injected about 60 min before meals
incretin mimetic adverse effects (4)
GI
hypoglycemia in combo therapy
hypersens. to injection
pancreatitis
DPP-IV inhibitor MOA & effects (2)
potentiates effects of incretin hormones
decrease postprandial & fasting glucose
modest decr. HA1c
-gliptin drugs are which class
DPP-IV inhibitors
DPP-IV inhibitors have what suffix
-gliptin
DPP-IV inhibitor contraindications
slow GI disease
renal impairment
Pramlintide (Symlin) drug type
amylin-like peptide
Pramlintide use
adjunct to insulin in Type 1 and 2
Pramlintide MOA & effects (4)
works with insulin to decrease gastric emptying
decreased postprandial glucose
decreased appetite/weight loss
decreased HbA1c
Pramlintide administration
injection 3x dailey w/ bolus of insulin